{"id":"second-dose","_chembl":{"chemblId":"CHEMBL5858588","moleculeType":null,"molecularWeight":"430.62"},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Second dose","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:30:58.719364+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:31:04.197447+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Second dose","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:31:04.815970+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5858588/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:31:05.530542+00:00"}},"_dailymed":null,"_scrapedAt":"2026-03-27T23:37:28.807Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:31:07.244134+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT05933954","phase":"NA","title":"The Effects of 5G Radiation on Skin","status":"RECRUITING","sponsor":"Prof. Olivier Gaide, MD-PhD","startDate":"2024-01-09","conditions":"Electromagnetic Radiation (5GFR2)","enrollment":42},{"nctId":"NCT07264543","phase":"PHASE2, PHASE3","title":"Early Methylene Blue in the Microhemodynamics of Septic Patients","status":"RECRUITING","sponsor":"Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva","startDate":"2026-01-09","conditions":"Septic Shock, Hypoperfusion","enrollment":50},{"nctId":"NCT07494045","phase":"PHASE2","title":"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants","status":"NOT_YET_RECRUITING","sponsor":"OPKO Health, Inc.","startDate":"2026-06","conditions":"CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism","enrollment":40},{"nctId":"NCT05111561","phase":"PHASE1","title":"Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-02","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm","enrollment":42},{"nctId":"NCT07495254","phase":"NA","title":"Effectiveness of Combined Super Inductive System (SIS) Therapy With Therapeutic Exercise and Health Education in Lateral Elbow Tendinopathy","status":"NOT_YET_RECRUITING","sponsor":"University of Vic - Central University of Catalonia","startDate":"2026-03-30","conditions":"Lateral Epicondylitis (Tennis Elbow), Lateral Epicondylalgia, Lateral Elbow Tendinopathy","enrollment":224},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT07113691","phase":"PHASE1","title":"Iadademstat + SBRT With Atezo in ES-SCLC","status":"RECRUITING","sponsor":"Yale University","startDate":"2026-01-20","conditions":"Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":15},{"nctId":"NCT07444814","phase":"PHASE1","title":"Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Whitehawk Therapeutics, Inc.","startDate":"2025-12-19","conditions":"Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic","enrollment":226},{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT01306019","phase":"PHASE1, PHASE2","title":"Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-09-25","conditions":"X-linked Severe Combined Immunodeficiency (XSCID)","enrollment":40},{"nctId":"NCT05131022","phase":"PHASE1","title":"A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies","status":"RECRUITING","sponsor":"Nurix Therapeutics, Inc.","startDate":"2022-04-13","conditions":"Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":572},{"nctId":"NCT07482501","phase":"NA","title":"Repetitive Transcranial Magnetic Stimulation in Cardiac Autonomic Dysfunction","status":"RECRUITING","sponsor":"Afyonkarahisar Health Sciences University","startDate":"2026-03-26","conditions":"Stroke, Autonomic Dysfunction, Hemiparesis","enrollment":44},{"nctId":"NCT04531046","phase":"PHASE2","title":"Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2021-03-10","conditions":"B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent","enrollment":62},{"nctId":"NCT07495579","phase":"PHASE2","title":"Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2026-04","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":146},{"nctId":"NCT06162494","phase":"PHASE4","title":"Recombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2024-03-18","conditions":"Varicella Zoster","enrollment":80},{"nctId":"NCT05630781","phase":"NA","title":"Orexin s Role in the Neurobiology of Substance Use Disorder","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2023-02-15","conditions":"Nicotine Dependence","enrollment":140},{"nctId":"NCT07497685","phase":"NA","title":"Effects of Different Caffeine Forms on Aerobic and Anaerobic Exercise Performance","status":"COMPLETED","sponsor":"University of Gaziantep","startDate":"2024-10-10","conditions":"Exercise Performance, Physical Performance","enrollment":14},{"nctId":"NCT05970224","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bioxodes S.A.","startDate":"2023-11-17","conditions":"Intracerebral Hemorrhage","enrollment":23},{"nctId":"NCT04628026","phase":"PHASE3","title":"Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2022-09-13","conditions":"Acute Myeloid Leukemia","enrollment":650},{"nctId":"NCT04190550","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-04","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","enrollment":24},{"nctId":"NCT03721068","phase":"PHASE1","title":"Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-02-19","conditions":"Neuroblastoma, Osteosarcoma","enrollment":18},{"nctId":"NCT05145647","phase":"NA","title":"To Observe the Benefit of Adding Brachytherapy After CCRT on Resectable Esophageal Cancer Patients Without Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2022-03-30","conditions":"Esophageal Cancer","enrollment":18},{"nctId":"NCT06616974","phase":"PHASE2","title":"A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)","status":"RECRUITING","sponsor":"Tectonic Therapeutic","startDate":"2024-09-04","conditions":"Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction","enrollment":180},{"nctId":"NCT07045038","phase":"NA","title":"Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2025-01-20","conditions":"Heart Failure NYHA Class II","enrollment":60},{"nctId":"NCT07296094","phase":"PHASE2","title":"Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-05-01","conditions":"Alcohol Use Disorder","enrollment":36},{"nctId":"NCT07498387","phase":"NA","title":"Management of Catatonic Features in Adolescents With Profound Autism","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tanta University","startDate":"2026-01-01","conditions":"Autism Spectrum Disorder, Catatonia","enrollment":30},{"nctId":"NCT04390724","phase":"","title":"Optimizing Y90 Therapy for Radiation Lobectomy","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2020-07-17","conditions":"HCC, Resection, Transplant","enrollment":104},{"nctId":"NCT05766046","phase":"NA","title":"Lung Cancer Prevention Screening Programme in Italy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ugo Pastorino","startDate":"2022-09-17","conditions":"Lung Cancer, COPD (Chronic Obstructive Pulmonary Disease) With Acute Lower Respiratory Infection, Cardiovascular Diseases","enrollment":7324},{"nctId":"NCT04801147","phase":"PHASE1, PHASE2","title":"Immunotherapy With Autologous Tumor Lysate-Loaded Dendritic Cells In Patients With Newly Diagnosed Glioblastoma Multiforme","status":"COMPLETED","sponsor":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","startDate":"2010-06-26","conditions":"Glioblastoma","enrollment":76},{"nctId":"NCT07328490","phase":"PHASE1, PHASE2","title":"Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma, Small Cell Carcinoma","enrollment":120},{"nctId":"NCT04234113","phase":"PHASE1","title":"Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors","status":"TERMINATED","sponsor":"SOTIO Biotech AG","startDate":"2019-06-13","conditions":"Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer","enrollment":115},{"nctId":"NCT07495488","phase":"NA","title":"Comparison Between Two Placement Concepts of Six Compressive","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2024-10-02","conditions":"Compressive Implants","enrollment":20},{"nctId":"NCT07000539","phase":"NA","title":"Indocyanine Green Fluorescence Angiography (ICG-FA) in Revisional Bariatric Surgery","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2025-05-06","conditions":"Obesity, Bariatric Surgery","enrollment":108},{"nctId":"NCT06709521","phase":"PHASE4","title":"Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-02-12","conditions":"Bacterial Infection","enrollment":150},{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":525},{"nctId":"NCT04645160","phase":"PHASE1, PHASE2","title":"Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-04","conditions":"Cholangiocarcinoma, Bile Duct Neoplasm, Biliary Tract Malignancy","enrollment":31},{"nctId":"NCT06788756","phase":"PHASE2, PHASE3","title":"L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML","status":"RECRUITING","sponsor":"Moleculin Biotech, Inc.","startDate":"2025-03-12","conditions":"Acute Myeloid Leukaemia (AML)","enrollment":312},{"nctId":"NCT04994977","phase":"PHASE1","title":"Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2023-05-04","conditions":"Atypical Choroid Plexus Papilloma, Choroid Plexus Carcinoma","enrollment":1},{"nctId":"NCT06864988","phase":"PHASE3","title":"4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2025-03-03","conditions":"Macular Neovascularization Secondary to Age-Related Macular Degeneration","enrollment":480},{"nctId":"NCT07107126","phase":"PHASE1","title":"Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes","status":"RECRUITING","sponsor":"Remedy Plan, Inc.","startDate":"2026-02-13","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":24},{"nctId":"NCT07492901","phase":"NA","title":"Impact of Ligament of Marshall Resection on Atrial Fibrillation Occurrence in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Controlled Trial","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2024-01-11","conditions":"Post Operative Arrythmia","enrollment":220},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT06052865","phase":"NA","title":"Serial Brain MRI in Hospitalized Preterm Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2020-09-14","conditions":"Preterm Birth Complication","enrollment":75},{"nctId":"NCT05678322","phase":"PHASE3","title":"Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2023-01-31","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT07112183","phase":"PHASE4","title":"Open Label Treprostinil Raynaud's Study","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-10-15","conditions":"Raynaud's Disease, Raynaud Phenomena, Raynauds","enrollment":30},{"nctId":"NCT05616650","phase":"PHASE2","title":"Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-10-19","conditions":"Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma","enrollment":42},{"nctId":"NCT05734196","phase":"PHASE1","title":"The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency","status":"RECRUITING","sponsor":"Inozyme Pharma","startDate":"2023-06-25","conditions":"Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy","enrollment":16},{"nctId":"NCT07490964","phase":"","title":"Polycystic Ovary Syndrome in Type 1 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2026-04-01","conditions":"Type 1 Diabetes Mellitus, Polycystic Ovary Syndrome (PCOS)","enrollment":60},{"nctId":"NCT01453088","phase":"PHASE2","title":"Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2010-06-24","conditions":"Multiple Myeloma","enrollment":63},{"nctId":"NCT07489924","phase":"PHASE4","title":"Microbiological Effect of 0.12% Chlorhexidine Digluconate and 0.05% Cetylpyridinium Chloride vs Probiotics (Lactobacillus Reuteri Prodentis) on Porphyromonas Gingivalis.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universidad de Colima","startDate":"2023-01-08","conditions":"Periodontal Diseases, Diabetes Mellitus Type 2","enrollment":20},{"nctId":"NCT02362438","phase":"PHASE1","title":"Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2015-04-24","conditions":"Giant Axonal Neuropathy, Gene Transfer","enrollment":14},{"nctId":"NCT03410615","phase":"PHASE2","title":"Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-05-28","conditions":"Oropharyngeal Squamous Cell Carcinoma","enrollment":129},{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":"Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab","enrollment":26},{"nctId":"NCT07490353","phase":"PHASE1","title":"Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2025-11-01","conditions":"Depression - Major Depressive Disorder, Anhedonia","enrollment":85},{"nctId":"NCT07490990","phase":"","title":"A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-06","conditions":"HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","enrollment":30},{"nctId":"NCT06654882","phase":"PHASE3","title":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-09","conditions":"Polyarticular Course Juvenile Idiopathic Arthritis (JIA)","enrollment":400},{"nctId":"NCT07059494","phase":"PHASE4","title":"Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-06","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT07488663","phase":"NA","title":"MODELING OBSESSIVE COMPULSIVE DISORDER AND EXPLORING TREATMENT RESPONSE USING INNOVATIVE THERAPIES AND STEM CELLS","status":"ENROLLING_BY_INVITATION","sponsor":"ASST Fatebenefratelli Sacco","startDate":"2023-04-30","conditions":"Obsessive - Compulsive Disorder","enrollment":60},{"nctId":"NCT02287311","phase":"PHASE1","title":"Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2015-02","conditions":"Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus","enrollment":38},{"nctId":"NCT05815602","phase":"PHASE3","title":"Ebastine Versus Mebeverine in IBS Patients","status":"RECRUITING","sponsor":"Guy Boeckxstaens","startDate":"2023-03-30","conditions":"IBS - Irritable Bowel Syndrome, IBS","enrollment":200},{"nctId":"NCT07487740","phase":"PHASE1","title":"A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants","status":"RECRUITING","sponsor":"Trevi Therapeutics","startDate":"2026-02-27","conditions":"Healthy Participants","enrollment":60},{"nctId":"NCT05992935","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-08-25","conditions":"Norovirus Acute Gastroenteritis","enrollment":1405},{"nctId":"NCT05626114","phase":"PHASE2","title":"A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-03-23","conditions":"Geographic Atrophy","enrollment":60},{"nctId":"NCT03663335","phase":"PHASE2","title":"Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-11-28","conditions":"Kidney Transplantation","enrollment":418},{"nctId":"NCT07145177","phase":"PHASE1","title":"177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-03-16","conditions":"Metastatic Prostate Cancer, Prostate Cancer","enrollment":30},{"nctId":"NCT07487077","phase":"PHASE4","title":"Extended Dosing Intervals Trial for Oral Cholera Vaccine, Kenya","status":"RECRUITING","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2025-10-31","conditions":"Cholera Vaccination","enrollment":1071},{"nctId":"NCT07215234","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-10-09","conditions":"Geographic Atrophy","enrollment":104},{"nctId":"NCT05283902","phase":"","title":"Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly","status":"COMPLETED","sponsor":"Federal University of Espirito Santo","startDate":"2022-03-19","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine-Preventable Diseases","enrollment":260},{"nctId":"NCT07200089","phase":"PHASE1","title":"Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-05-31","conditions":"Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory","enrollment":40},{"nctId":"NCT03570892","phase":"PHASE3","title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-07","conditions":"Non-Hodgkin Lymphoma","enrollment":331},{"nctId":"NCT07485504","phase":"PHASE1","title":"Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies","status":"NOT_YET_RECRUITING","sponsor":"Tcelltech Inc.","startDate":"2026-04-15","conditions":"Relapsed or Refractory Hematologic Malignancies","enrollment":15},{"nctId":"NCT06738160","phase":"PHASE2","title":"The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-15","conditions":"NSCLC, Stereotactic Body Radiation Therapy (SBRT), Immunotherapy","enrollment":27},{"nctId":"NCT07368959","phase":"PHASE3","title":"AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction","status":"RECRUITING","sponsor":"Aurion Biotech","startDate":"2026-02-19","conditions":"Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction","enrollment":120},{"nctId":"NCT00720785","phase":"PHASE1","title":"Natural Killer Cells and Bortezomib to Treat Cancer","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2008-08-01","conditions":"Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca","enrollment":35},{"nctId":"NCT07486089","phase":"PHASE1, PHASE2","title":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":"Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC)","enrollment":60},{"nctId":"NCT05537740","phase":"PHASE1","title":"A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2022-10-11","conditions":"Advanced Solid Tumors","enrollment":129},{"nctId":"NCT06278233","phase":"NA","title":"Bihemispheric Transcranial Direct Current Stimulation* on Speech Fluency","status":"COMPLETED","sponsor":"Biruni University","startDate":"2024-01-23","conditions":"Stuttering, Adult","enrollment":36},{"nctId":"NCT06239376","phase":"NA","title":"Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients","status":"RECRUITING","sponsor":"Mỹ Đức Hospital","startDate":"2024-02-19","conditions":"Adenomyosis, IVF, Frozen Embryo Transfer","enrollment":222},{"nctId":"NCT07221175","phase":"NA","title":"Operator Radiation Dose Using Ultra-Low Fluoroscopic Pulse Rate Versus Standard In Performing Coronary Angiography Via Right Radial Artery","status":"WITHDRAWN","sponsor":"Maimonides Medical Center","startDate":"2025-11-01","conditions":"Radiation Exposure, Radiation Exposure to Operator","enrollment":""},{"nctId":"NCT06705686","phase":"PHASE1","title":"Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"TechnoGenesys, Inc.","startDate":"2026-03-13","conditions":"Metastatic Castration-resistant Prostate Cancer (CRPC), Metastatic Castration-resistant Prostate Carcinoma","enrollment":40},{"nctId":"NCT07469293","phase":"PHASE3","title":"Efficacy and Safety of Intra-arterial Tenecteplase in Acute Ischemic Stroke Patients With Medium Vessel Occlusion Stroke (DATE-MeVO)","status":"NOT_YET_RECRUITING","sponsor":"Southwest Hospital, China","startDate":"2026-03-25","conditions":"Acute Ischemic Stroke","enrollment":488},{"nctId":"NCT07380984","phase":"PHASE2","title":"PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-03","conditions":"Natural Killer/T-cell Lymphoma","enrollment":47},{"nctId":"NCT07481955","phase":"PHASE2","title":"Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial","status":"NOT_YET_RECRUITING","sponsor":"Freya Biosciences ApS","startDate":"2026-03-16","conditions":"Bacterial Vaginosis (BV)","enrollment":120},{"nctId":"NCT03574623","phase":"NA","title":"Therapies for Recovery of Hand Function After Stroke","status":"COMPLETED","sponsor":"MetroHealth Medical Center","startDate":"2019-02-15","conditions":"Stroke, Upper Extremity Paresis, Hemiplegia","enrollment":132},{"nctId":"NCT07484373","phase":"NA","title":"Effects of Hip Abductor Strengthening Exercises in Patients With Piriformis Syndrome","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2025-01-13","conditions":"Piriformis Syndrome","enrollment":48},{"nctId":"NCT04278768","phase":"PHASE1, PHASE2","title":"Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)","status":"SUSPENDED","sponsor":"Curis, Inc.","startDate":"2020-07-06","conditions":"Acute Myelogenous Leukemia, Myelodysplastic Syndrome","enrollment":366},{"nctId":"NCT04986631","phase":"EARLY_PHASE1","title":"Pharmacokinetics and Pharmacodynamics of Topiramate for Weight Loss in Youth: PHARMATOP","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Minnesota","startDate":"2022-04-04","conditions":"Obesity, Childhood","enrollment":62},{"nctId":"NCT07203625","phase":"PHASE4","title":"Tenecteplase Before Interhospital Transfer in Acute Basilar Artery Occlusion at 4.5 to 24 Hours","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-20","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":316},{"nctId":"NCT07253181","phase":"PHASE3","title":"Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-06","conditions":"Acute Ischemic Stroke, Large Vessel Occlusion, Transportation of Patients","enrollment":572},{"nctId":"NCT06309485","phase":"PHASE2","title":"Phase 2 Study of WGI-0301 for Advanced HCC","status":"RECRUITING","sponsor":"Zhejiang Haichang Biotech Co., Ltd.","startDate":"2024-07-31","conditions":"Advanced Hepatocellular Carcinoma (HCC)","enrollment":60},{"nctId":"NCT05923190","phase":"PHASE2","title":"Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2023-06-14","conditions":"Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma","enrollment":60},{"nctId":"NCT06406114","phase":"PHASE2","title":"Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-05-05","conditions":"Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity","enrollment":300},{"nctId":"NCT05629845","phase":"NA","title":"Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-11-22","conditions":"Hepatocellular Carcinoma, Variceal Bleeding","enrollment":84},{"nctId":"NCT06892548","phase":"PHASE1, PHASE2","title":"A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-05-02","conditions":"Advanced Lung Cancer","enrollment":594},{"nctId":"NCT07307170","phase":"NA","title":"The Analgesic Efficacy and Safety of Mirogabalin in Patients With Herpes Zoster","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-12-15","conditions":"Herpes Zoster, Mirogabalin, Pain","enrollment":750},{"nctId":"NCT07477639","phase":"PHASE1, PHASE2","title":"Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis","status":"RECRUITING","sponsor":"Tr1X, Inc.","startDate":"2026-03","conditions":"Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Multiple Sclerosis","enrollment":39},{"nctId":"NCT05529927","phase":"PHASE2","title":"Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Parnassia Addiction Research Centre","startDate":"2026-05","conditions":"Cocaine Use Disorder","enrollment":204},{"nctId":"NCT06071624","phase":"PHASE1","title":"Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.","status":"RECRUITING","sponsor":"Huda Salman","startDate":"2024-02-21","conditions":"Chronic Myelomonocytic Leukemia","enrollment":30},{"nctId":"NCT06658405","phase":"PHASE2","title":"Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions","status":"RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2025-01-13","conditions":"Cervical Lesion","enrollment":85},{"nctId":"NCT05322252","phase":"PHASE4","title":"Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2022-07-01","conditions":"Abortion, Second Trimester, PPROM, Rupture, Spontaneous","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ADRENAL INSUFFICIENCY NEONATAL"},{"count":1,"reaction":"ANAEMIA NEONATAL"},{"count":1,"reaction":"CARDIO-RESPIRATORY ARREST NEONATAL"},{"count":1,"reaction":"FUNGAL SEPSIS"},{"count":1,"reaction":"HAEMATOCRIT DECREASED"},{"count":1,"reaction":"MALAISE"},{"count":1,"reaction":"NECROTISING ENTEROCOLITIS NEONATAL"},{"count":1,"reaction":"NEONATAL CHOLESTASIS"},{"count":1,"reaction":"NEONATAL DISORDER"},{"count":1,"reaction":"PULMONARY EMBOLISM"}],"crossReferences":{"chemblId":"CHEMBL5858588"},"_approvalHistory":[],"publicationCount":9557,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"marketed","status":"active","brandName":"Second dose","genericName":"Second dose","companyName":"BioSyngen Pte Ltd","companyId":"biosyngen-pte-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:31:07.244134+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}